Cancer Treatment Reviews

Papers
(The H4-Index of Cancer Treatment Reviews is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review202
Systemic therapy for older patients with early breast cancer193
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in192
Editorial Board177
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis128
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty115
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer108
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group108
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)95
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas93
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer91
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives81
De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis80
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer73
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials72
Proton beam therapy for children and adolescents and young adults (AYAs): JASTRO and JSPHO Guidelines70
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.68
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches64
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features60
Editorial Board60
Emerging antibody-based therapies for the treatment of acute myeloid leukemia59
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis59
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?59
If it’s a target, it’s a pan-cancer target: Tissue is not the issue58
Optimizing care in early phase cancer trials: The role of palliative care55
Uncertainties and controversies in axillary management of patients with breast cancer53
FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma53
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis53
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC52
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients’ data from 3 phase III studies52
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment51
Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges50
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials50
Editorial Board46
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes46
Roadmap to cure multiple myeloma45
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck45
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations44
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?44
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review43
Editorial Board42
The immunogram of inflammatory breast cancer42
0.10191512107849